Xeris Biopharma officer proposes $803K share sale

Three earlier sales appear under the 10b5-1 heading; the proposed shares came from restricted stock unit vesting in January 2025.

Available on EDGAR 11/02/2026 - 04:39 PM EST Accepted by SEC EDGAR 11/02/2026 - 04:39 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Beth Hecht, identified as an officer of Xeris Biopharma Holdings, Inc. (XERS), reported a proposed sale of 75,000 common shares with an aggregate market value of $803,250.00. The listed broker is Morgan Stanley Smith Barney LLC Executive Financial Services, and the approximate sale date is November 2, 2026. The shares were acquired upon vesting of restricted stock units during January 3 through January 31, 2025.

The notice also lists three earlier sales under the “10b5-1 Sales” heading: 16,666 shares on August 3, September 1 and October 1, 2026, with reported gross proceeds of $133,553.66, $141,433.67 and $156,791.73, respectively.

Key Figures

Proposed sale: 75,000 shares Aggregate market value: $803,250.00 Earlier reported sale: 16,666 shares; $133,553.66 +2 more

5 metrics

Proposed sale 75,000 shares Common shares; approximate sale date November 2, 2026

Aggregate market value $803,250.00 Proposed sale

Earlier reported sale 16,666 shares; $133,553.66 August 3, 2026

Earlier reported sale 16,666 shares; $141,433.67 September 1, 2026

Earlier reported sale 16,666 shares; $156,791.73 October 1, 2026

Key Terms

restricted stock units, 10b5-1 Sales, Rule 144

3 terms

restricted stock units financial

"acquired upon the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

10b5-1 Sales regulatory

"10b5-1 Sales for BETH HECHT"

10b5-1 sales are pre-arranged stock-trading plans that let company insiders automatically buy or sell shares according to a fixed schedule or formula, even if they later learn confidential information. Think of it as setting up an automatic thermostat for trades: it creates a clear, documented path that can protect insiders from insider-trading accusations and gives investors a signal about predictable insider activity—though it can also simply be a way for insiders to diversify or raise cash.

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many XERS shares did Beth Hecht report for sale?

Beth Hecht reported a proposed sale of 75,000 common shares, with an aggregate market value of $803,250.00 and an approximate sale date of November 2, 2026.

How were the shares in Beth Hecht’s proposed XERS sale acquired?

The remarks state that the securities were acquired upon vesting of restricted stock units during January 3 through January 31, 2025.

What earlier XERS sales did Beth Hecht report?

The notice lists three earlier sales under the “10b5-1 Sales” heading: 16,666 shares on August 3, 2026, for $133,553.66; 16,666 shares on September 1, 2026, for $141,433.67; and 16,666 shares on October 1, 2026, for $156,791.73.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001652410
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	XERIS BIOPHARMA HOLDINGS, INC.
SEC File Number	001-40880
Address of Issuer	1375 West Fulton Street, Suite 1300 Chicago ILLINOIS 60607
Phone	8444455704
Name of Person for Whose Account the Securities are To Be Sold	BETH HECHT
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	75000	803250.00	182320306	11/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/03/2025	Restricted Stock Units	Issuer			75000	01/03/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for BETH HECHT 1375 West Fulton Street, Suite 1300 Chicago IL 60607	Common	10/01/2026	16666	156791.73
10b5-1 Sales for BETH HECHT 1375 West Fulton Street, Suite 1300 Chicago IL 60607	Common	09/01/2026	16666	141433.67
10b5-1 Sales for BETH HECHT 1375 West Fulton Street, Suite 1300 Chicago IL 60607	Common	08/03/2026	16666	133553.66

144: Remarks and Signature

Remarks	The securities to be sold were acquired upon the vesting of restricted stock units during the period of 1/3/2025 through 1/31/2025.
Date of Notice	11/02/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/12/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Beth Hecht
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)